- Home
- WHF vs QNCX Comparison
WHF vs QNCX Comparison
Compare WHF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | QNCX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 167.0M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WHF | QNCX |
|---|---|---|
| Price | $6.43 | $0.14 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $10.00 |
| AVG Volume (30 Days) | 108.4K | ★ 5.1M |
| Earning Date | 03-06-2026 | 03-23-2026 |
| Dividend Yield | ★ 16.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $76,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.39 | $0.13 |
| 52 Week High | $11.31 | $4.55 |
Technical Indicators
Market Signals| Indicator | WHF | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 21.13 |
| Support Level | $6.40 | $0.14 |
| Resistance Level | $6.83 | $0.18 |
| Average True Range (ATR) | 0.16 | 0.37 |
| MACD | -0.04 | -0.28 |
| Stochastic Oscillator | 8.30 | 0.09 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.